Bio-Thera(SH:688177)2025-01-17 09:55Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between -420 million and -580 million CNY, indicating an increase in losses compared to the previous year[2]. - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -465 million and -625 million CNY[2]. - The previous year's net profit attributable to shareholders was -394.53 million CNY, with a total profit of -394.42 million CNY[7]. - The previous year's net profit, excluding non-recurring gains and losses, was -471.83 million CNY[7]. - The company reported a loss per share of -0.95 CNY in the previous year[8]. Revenue Expectations - The estimated operating revenue for 2024 is expected to be between 710 million and 790 million CNY, representing a year-on-year growth of 0.74% to 12.09%[9]. - The increase in revenue is primarily driven by the sustained growth in sales of Adalimumab injection (Gelerit®) and the new overseas supply business of Tocilizumab injection, although the overseas collaboration is still in the early stages[9]. Research and Development - The company has a rich pipeline for drug research and development, with continuous high investment in R&D expenses, contributing to the increase in losses year-on-year[9]. Performance Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this performance forecast as of the announcement date[10]. - The forecast data is preliminary and subject to change pending the audited annual report for 2024[11].